Search - tctmd.com

Displaying 941 - 960 of 1148

Sort: Relevancy | Date

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

November 07, 2016

Debate- Is Upper Extremity Dysfunction After Radial Access Frequent and Clinically Important? Yes, We Have to Start Paying Attention to This Phenomenon!

Presentation TCT 2016

Debate- Is Upper Extremity Dysfunction After Radial Access Frequent and Clinically Important? Yes, We Have to Start Paying Attention to This Phenomenon!

Presenter: Adrian P. Banning, Nick Curzen, Robert-Jan van Geuns

November 01, 2016

News Conference News TCT 2016

Interventionalists Push Transradial PCI in Wider Range of Settings, Including ACS, CTOs, and Calcified Lesions

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Start With the Debate - DAPT Duration With Contemporary DES: Short DAPT For Most!

Presentation TCT 2016

Start With the Debate - DAPT Duration With Contemporary DES: Short DAPT For Most!

Presenter: John A. Bittl, Daniel I. Simon, Salvatore Cassese

October 30, 2016

Start With the Debate - DAPT Duration With Contemporary DES: Prolonged DAPT For Most!

Presentation TCT 2016

Start With the Debate - DAPT Duration With Contemporary DES: Prolonged DAPT For Most!

Presenter: John A. Bittl, Daniel I. Simon, Laura Mauri

October 30, 2016

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presentation TCT 2016

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White

October 30, 2016

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presentation TCT 2016

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo

October 30, 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presentation TCT 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann

October 30, 2016

Case #1: Antegrade Dissection and Reentry: Stingray Is Not STAR

Presentation TCT 2016

Case #1: Antegrade Dissection and Reentry: Stingray Is Not STAR

Presenter: Colm Hanratty, Simon J. Walsh, James C. Spratt

October 30, 2016

Impella CP Fails to Show Benefit in Exploratory Study of Patients With Severe Cardiogenic Shock

News Conference News TCT 2016

Impella CP Fails to Show Benefit in Exploratory Study of Patients With Severe Cardiogenic Shock

October 29, 2016

News Daily News

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Michael O'Riordan

October 28, 2016

News Daily News

Fallout From Rehospitalization After Acute MI May Extend Beyond Economics

Yael L. Maxwell

October 28, 2016

News Daily News

Hybrid Algorithm for CTO PCI Delivers High Success Rates, Registry Affirms

October 28, 2016

News Daily News

Study Explores Possible Mechanism to Explain Air Pollution-CVD Link

October 27, 2016

News Daily News

New Guideline Gives the Greenlight to Calcium Supplements

October 26, 2016

News Daily News

How PCI Mortality Is Publicly Reported Requires Reworking, ACC’s Interventional Council Says

October 25, 2016

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Daily News

Midlife Hypertension Linked to Late-Life Cognitive Decline

October 11, 2016

News Daily News

STEMI Patients Far From PCI Centers Fare Well With Pharmacoinvasive Strategy

October 05, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.